Ligand Pharma (LGND) has shared an announcement.
Ligand Pharmaceuticals has struck a deal to acquire APEIRON Biologics for $100 million, gaining royalty rights to a neuroblastoma treatment, QARZIBA®, with potential additional payments of up to $28 million based on future sales. The transaction, expected to close in July 2024, also involves a $4 million investment in APEIRON’s spin-off, invIOs Holding AG. This strategic move is anticipated to boost Ligand’s earnings, leading to an increased revenue guidance for 2024 and a higher earnings per share forecast.
For an in-depth examination of LGND stock, go to TipRanks’ Stock Analysis page.
